IMMU is my biggest holding.
REGN: Are you afraid of challenges to Eylea from generic VEGF targeted mabs or lower priced alternatives like Bev.?
KDMN: What do you project to be the NPV for its BTD therapy prior to patent expiration?
Of the big cap names, I like GILD. I think there may be more revenue for Redesivir left than people expect as vaccines may not be the magic bullet everyone expects and require periodic redosing; SARS-COV-2 may also become endemic instead of being eradicated quickly. Pfizer announced their intention to continue their search for antivirals along with developing their vaccine candidate. Remdesivir may continue to be best in class for quite a while as development of other antivirals could be lengthy and costly, and Gilead is investigating other formulations such as an inhalable version which may expand its usage.
Its HIV revenues will recover and legacy Hep-C therapies despite being a shadow of their peak around 2015 have quite a bit of revenue left. Gilead's oncology pipeline is also differentiated and promising, consisting of several new line of immuno-oncology therapies (CAR-T, CD47) that may find traction in the next decade.